BioLight Life Sciences Ltd (TA:BOLT) — Market Cap & Net Worth
Market Cap & Net Worth: BioLight Life Sciences Ltd (BOLT)
BioLight Life Sciences Ltd (TA:BOLT) has a market capitalization of $8.96 Million (ILA3.34 Billion) as of July 13, 2026. Listed on the TA stock exchange, this Israel-based company holds position #27378 globally and #393 in its home market, demonstrating a -10.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioLight Life Sciences Ltd's stock price ILA369.30 by its total outstanding shares 9047603 (9.05 Million). Review BOLT total liabilities to assess the company's total debt and financial obligations.
BioLight Life Sciences Ltd Market Cap History: 2015 to 2026
BioLight Life Sciences Ltd's market capitalization history from 2015 to 2026. Data shows change from $74.53 Million to $8.96 Million (-18.64% CAGR).
BioLight Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioLight Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
60.92x
BioLight Life Sciences Ltd's market cap is 60.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $30.80 Million | $2.11 Million | -$21.82 Million | 14.59x | N/A |
| 2017 | $35.33 Million | $1.21 Million | -$17.26 Million | 29.22x | N/A |
| 2018 | $30.39 Million | $3.69 Million | $65.39 Million | 8.24x | 0.46x |
| 2019 | $20.86 Million | $297.00K | -$12.59 Million | 70.24x | N/A |
| 2020 | $19.04 Million | $31.00K | -$13.38 Million | 614.23x | N/A |
| 2021 | $27.99 Million | $3.00K | $382.00K | 9330.59x | 73.28x |
| 2022 | $16.49 Million | $63.00K | -$7.85 Million | 261.81x | N/A |
| 2023 | $12.83 Million | $118.00K | -$26.02 Million | 108.74x | N/A |
| 2024 | $13.34 Million | $219.00K | -$7.14 Million | 60.92x | N/A |
Competitor Companies of BOLT by Market Capitalization
Companies near BioLight Life Sciences Ltd in the global market cap rankings as of July 13, 2026.
Key companies related to BioLight Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #429 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #549 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #567 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $485.39 |
| #429 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $664.52 |
| #549 | Argen-X | BR:ARGX | $49.55 Billion | €763.80 |
| #567 | UCB SA | BR:UCB | $47.34 Billion | €237.10 |
BioLight Life Sciences Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, BioLight Life Sciences Ltd's market cap moved from $74.53 Million to $ 8.96 Million, with a yearly change of -18.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA8.96 Million | +7.14% |
| 2025 | ILA8.36 Million | -37.33% |
| 2024 | ILA13.34 Million | +3.97% |
| 2023 | ILA12.83 Million | -22.21% |
| 2022 | ILA16.49 Million | -41.07% |
| 2021 | ILA27.99 Million | +47.01% |
| 2020 | ILA19.04 Million | -8.72% |
| 2019 | ILA20.86 Million | -31.36% |
| 2018 | ILA30.39 Million | -13.98% |
| 2017 | ILA35.33 Million | +14.73% |
| 2016 | ILA30.80 Million | -58.68% |
| 2015 | ILA74.53 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 12th, 2026 the market cap of BioLight Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.96 Million USD |
| MoneyControl | $8.96 Million USD |
| MarketWatch | $8.96 Million USD |
| marketcap.company | $8.96 Million USD |
| Reuters | $8.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more